RFA's as of February 2020
| Announcement | Issuing | Release | Opening Date | Expiration | Activity | Title |
| RFA-DA-20-022 | NIDA | 11/7/2019 | 2/11/2020 | 3/12/2020 | R01 | Assessing the Effects of Cannabinoids on HIV-Induced Inflammation (R01 Clinical Trial Optional) |
| RFA-AA-20-006 | NIAAA | 11/12/2019 | 2/24/2020 | 3/25/2020 | R01 | Impact of Alcohol on the Onset and Progression of Alzheimers Disease and Its Related Dementias (R01 - Clinical Trial Optional) |
| RFA-AA-20-007 | NIAAA | 1/16/2020 | 2/26/2020 | 3/27/2020 | U01 | Medications Development for the Treatment of Alcohol Use Disorder (AUD) or Alcohol-Related Organ Damage (AROD), or the Combination of AUD and AROD (U01 Clinical Trial Optional) |
| RFA-DA-19-003 | NIDA | 2/15/2018 | 6/17/2018 | 7/18/2020 | R61/R33 | Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional) |
| RFA-DA-18-019 | NIDA | 12/6/2017 | 7/14/2018 | 8/15/2020 | DP1 | NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional) |
| RFA-DA-18-022 | NIDA | 3/14/2018 | 7/22/2018 | 8/22/2020 | R01 | Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01, Clinical Trial Optional) |
| RFA-DA-18-020 | NIDA | 12/6/2017 | 6/25/2018 | 9/8/2020 | UG3/UH3 | NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional) |
| RFA-DA-19-019 | NIDA | 12/10/2018 | 12/10/2018 | 9/9/2021 | R43/R44 | HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional) |
| RFA-DA-19-020 | NIDA | 12/10/2018 | 12/10/2018 | 9/9/2021 | R41/R42 | HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R41/R42 - Clinical Trial Optional) |